2,2 '-Methylenebis (6-tert-butyl 4-methylphenol) enhances the antitumor efficacy of belotecan, a derivative of camptothecin, by inducing autophagy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, Minsu | - |
dc.contributor.author | Kim, Hyunju | - |
dc.contributor.author | Park, Rackhyun | - |
dc.contributor.author | Jo, Daum | - |
dc.contributor.author | Lee, Eun-Ju | - |
dc.contributor.author | Oh, Won Keun | - |
dc.contributor.author | Park, Junsoo | - |
dc.date.available | 2019-03-08T06:58:34Z | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/3476 | - |
dc.description.abstract | Autophagy regulation is important for tumor cell survival. Activation and inhibition of autophagy can sensitize tumor cells to anticancer drugs. However, few autophagy-regulating small molecules are available to increase the efficacy of anticancer drugs. Here, we report that 2,2'-methylenebis (6-tert-butyl 4-methylphenol), hereafter referred to as methylenebis, is a novel autophagy-regulating small molecule that sensitizes tumor cells to belotecan, which is a derivative of camptothecin, a topoisomerase I inhibitor. Methylenebis activates autophagic flux by increasing the level of LC3-II and forming autolysosome puncta. Moreover, methylenebis enhances the antitumor efficacy of belotecan by activating both autophagy and apoptosis. Interestingly, methylenebis increased the level of LC3-II and belotecan independently decreased the level of p62, suggesting that methylenebis and belotecan target different steps of autophagy. Finally, we searched for compounds that are structurally similar to methylenebis. Our results imply that the specific structure of methylenebis contributes to its ability to activate autophagy. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.title | 2,2 '-Methylenebis (6-tert-butyl 4-methylphenol) enhances the antitumor efficacy of belotecan, a derivative of camptothecin, by inducing autophagy | - |
dc.type | Article | - |
dc.identifier.doi | 10.18632/oncotarget.22858 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.8, no.70, pp 115068 - 115078 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000419571000059 | - |
dc.identifier.scopusid | 2-s2.0-85039757446 | - |
dc.citation.endPage | 115078 | - |
dc.citation.number | 70 | - |
dc.citation.startPage | 115068 | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 8 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | autophagy | - |
dc.subject.keywordAuthor | cancer | - |
dc.subject.keywordAuthor | methylenebis | - |
dc.subject.keywordAuthor | belotecan | - |
dc.subject.keywordAuthor | camptothecin | - |
dc.subject.keywordPlus | DOUBLE-EDGED-SWORD | - |
dc.subject.keywordPlus | CANCER-THERAPY | - |
dc.subject.keywordPlus | TOPOISOMERASE-I | - |
dc.subject.keywordPlus | CYTOTOXIC AUTOPHAGY | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | LC3 | - |
dc.subject.keywordPlus | CHLOROQUINE | - |
dc.subject.keywordPlus | RADIATION | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.